Show simple item record

dc.contributor.authorWilson, Justin J.
dc.contributor.authorLippard, Stephen J.
dc.date.accessioned2013-11-18T14:05:00Z
dc.date.available2013-11-18T14:05:00Z
dc.date.issued2012-05
dc.date.submitted2012-02
dc.identifier.issn0022-2623
dc.identifier.issn1520-4804
dc.identifier.urihttp://hdl.handle.net/1721.1/82155
dc.description.abstractFive cationic platinum(II) complexes of general formula, [Pt(NH[subscript 3])[subscript 2](β-diketonate)]X are reported, where X is a noncoordinating anion and β-diketonate = acetylacetonate (acac), 1,1,1,-trifluoroacetylacetonate (tfac), benzoylacetonate (bzac), 4,4,4-trifluorobenzoylacetonate (tfbz), or dibenzoylmethide (dbm), corresponding, respectively, to complexes 1–5. The log P values and the stabilities of 1–5 in aqueous solution were evaluated. The phenyl ring substituents of 3–5 increase the lipophilicity of the resulting complexes, whereas the trifluoromethyl groups of 2 and 4 decrease the stability of the complexes in aqueous solution. The uptake of 1–5 in HeLa cells increases as the lipophilicity of the investigated complex increases. Cancer cell cytotoxicity studies indicate that 1 and 3 are the least active complexes whereas 2, 4, and 5 are comparable in activity to cisplatin.en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (Grant CA034992)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant 1S10RR13886-01)en_US
dc.language.isoen_US
dc.publisherAmerican Chemical Society (ACS)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1021/jm3002857en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleIn Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligandsen_US
dc.typeArticleen_US
dc.identifier.citationWilson, Justin J., and Stephen J. Lippard. “In Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligands.” Journal of Medicinal Chemistry 55, no. 11 (June 14, 2012): 5326-5336.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemistryen_US
dc.contributor.mitauthorWilson, Justin J.en_US
dc.contributor.mitauthorLippard, Stephen J.en_US
dc.relation.journalJournal of Medicinal Chemistryen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsWilson, Justin J.; Lippard, Stephen J.en_US
dc.identifier.orcidhttps://orcid.org/0000-0002-2693-4982
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record